350 related articles for article (PubMed ID: 28940172)
1. GP2015: An Etanercept Biosimilar.
Deeks ED
BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
[TBL] [Abstract][Full Text] [Related]
2. SB5: An Adalimumab Biosimilar.
Frampton JE
BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
[TBL] [Abstract][Full Text] [Related]
3. GP2015 as a promising therapy for rheumatoid arthritis.
Fitton J; Giollo A; Buch MH
Expert Opin Biol Ther; 2018 Apr; 18(4):477-481. PubMed ID: 29558865
[TBL] [Abstract][Full Text] [Related]
4. Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases.
Burness CB; Duggan ST
BioDrugs; 2016 Aug; 30(4):371-8. PubMed ID: 27455991
[TBL] [Abstract][Full Text] [Related]
5. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).
Hofmann HP; Kronthaler U; Fritsch C; Grau R; Müller SO; Mayer R; Seidl A; Da Silva A
Expert Opin Biol Ther; 2016 Oct; 16(10):1185-95. PubMed ID: 27463856
[TBL] [Abstract][Full Text] [Related]
6. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
[TBL] [Abstract][Full Text] [Related]
7. Etanercept for the treatment of rheumatoid arthritis.
Zhao S; Mysler E; Moots RJ
Immunotherapy; 2018 Mar; 10(6):433-445. PubMed ID: 29482402
[TBL] [Abstract][Full Text] [Related]
8. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
[TBL] [Abstract][Full Text] [Related]
9. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
Ditto MC; Parisi S; Priora M; Sanna S; Peroni CL; Laganà A; D'Avolio A; Fusaro E
Sci Rep; 2020 Sep; 10(1):16178. PubMed ID: 32999362
[TBL] [Abstract][Full Text] [Related]
11. GP2017: An Adalimumab Biosimilar.
Heo YA
BioDrugs; 2018 Dec; 32(6):635-638. PubMed ID: 30460599
[TBL] [Abstract][Full Text] [Related]
12. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
McClean AR; Cheng L; Bansback N; Clement F; Tadrous M; Harrison M; Law MR
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):2011-2021. PubMed ID: 36752358
[TBL] [Abstract][Full Text] [Related]
13. PF-06438179/GP1111: An Infliximab Biosimilar.
Al-Salama ZT
BioDrugs; 2018 Dec; 32(6):639-642. PubMed ID: 30284704
[TBL] [Abstract][Full Text] [Related]
14. SB2: An Infliximab Biosimilar.
Lamb YN; Scott LJ; Deeks ED
BioDrugs; 2017 Oct; 31(5):461-464. PubMed ID: 28803431
[TBL] [Abstract][Full Text] [Related]
15. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
Blair HA; Deeks ED
BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
[TBL] [Abstract][Full Text] [Related]
16. FKB327: An Adalimumab Biosimilar.
Al-Salama ZT
BioDrugs; 2019 Feb; 33(1):113-116. PubMed ID: 30712241
[TBL] [Abstract][Full Text] [Related]
17. New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept.
Miranda-Hernández MP; López-Morales CA; Perdomo-Abúndez FC; Salazar-Flores RD; Ramírez-Ibanez ND; Pérez NO; Molina-Pérez A; Revilla-Beltri J; Flores-Ortiz LF; Medina-Rivero E
J Immunol Res; 2016; 2016():9697080. PubMed ID: 27382576
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
Strand V; Balsa A; Al-Saleh J; Barile-Fabris L; Horiuchi T; Takeuchi T; Lula S; Hawes C; Kola B; Marshall L
BioDrugs; 2017 Aug; 31(4):299-316. PubMed ID: 28612180
[TBL] [Abstract][Full Text] [Related]
19. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
Chadwick L; Zhao S; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Nov; 20(12):84. PubMed ID: 30411183
[TBL] [Abstract][Full Text] [Related]
20. CT-P10 (Truxima™): A Rituximab Biosimilar.
Deeks ED
BioDrugs; 2017 Jun; 31(3):275-278. PubMed ID: 28497220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]